Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04660552 · ClinicalTrials.gov registry record · NA
Transcranial Photobiomodulation for Reducing Autism Symptoms in Children
A NA study, sponsored by JelikaLite.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
NCT04660552 is a NA study that has completed, run by JelikaLite. The registered enrollment target is 34 participants.
The verdict
NCT04660552, a NA study, has completed, sponsored by JelikaLite.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
Study Summary
The hypothesis of the study is that photobiomodulation reduces symptoms of autism. Participants will be children between the ages of 2 and 6, who have been diagnosed with moderate to severe autism. Transcranial photobiomodulation will be administered to the children in the experimental condition twice a week for 8 weeks. Results will be measured through parental interviews, standardized CARS2 (Childhood Autism Rating Scales, 2nd Edition) and data collected from EEG.
Interventions
- DEVICE Cognilum TM: Light Treatment Condition
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2020-11-15 |
| Est. Completion | 2023-12-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04660552
The ClinicalTrials.gov registry entry for NCT04660552 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is JelikaLite, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cognilum TM: Light Treatment Condition is the first listed.
NCT04660552 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04660552 about?
NCT04660552 is a clinical study titled "Transcranial Photobiomodulation for Reducing Autism Symptoms in Children". The hypothesis of the study is that photobiomodulation reduces symptoms of autism. Participants will be children between the ages of 2 and 6, who have been diagnosed with moderate to severe autism. Transcranial photobiomodulation will be administered to the children in the experimental condition twi...
What is the current status of trial NCT04660552?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2020-11-15. Estimated completion is 2023-12-30.
What interventions are being tested in trial NCT04660552?
The interventions under investigation include: Cognilum TM: Light Treatment Condition (DEVICE).
Who is sponsoring clinical trial NCT04660552?
This trial is sponsored by JelikaLite, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.